Experimental Workflow for Preclinical Studies of Human Antifibrotic Therapies
Lien Reolizo1, Michitaka Matsuda1, Ekihiro Seki2,3
1Karsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Abstract:
Chronic liver diseases accompanied by liver fibrosis have caused significant morbidity and mortality in the world with increasing prevalence. Nonetheless, there are no approved antifibrotic therapies. Although numerous preclinical studies showed satisfactory results in targeting fibrotic pathways, these animal studies have not led to success in humans. In this chapter, we summarize the experimental approaches currently available, including in vitro cell culture models, in vivo animal models, and new experimental tools relevant to humans, and discuss how we translate laboratory results to clinical trials. We will also address the obstacles in transitioning promising therapies from preclinical studies to human antifibrotic treatments.
Insights
Developing effective antifibrotic therapies for chronic liver diseases remains a challenge. This review examines experimental models and discusses the translation of preclinical findings to human clinical trials for liver fibrosis.
Area of Science:
- Hepatology
- Fibrosis research
- Translational medicine
Background:
- Chronic liver diseases with fibrosis are a major global health concern.
- Current treatments lack approved antifibrotic therapies.
- Preclinical studies show promise but often fail in human trials.
Purpose of the Study:
- To review current experimental approaches for studying liver fibrosis.
- To discuss the translation of preclinical research to clinical applications.
- To identify obstacles in developing antifibrotic treatments.
Main Methods:
- Summary of in vitro cell culture models.
- Overview of in vivo animal models.
- Discussion of human-relevant experimental tools.
Main Results:
- Preclinical studies targeting fibrotic pathways have yielded unsatisfactory results in human trials.
- Challenges exist in translating laboratory findings to clinical success.
- Obstacles in antifibrotic therapy development are highlighted.
Conclusions:
- Effective translation of preclinical liver fibrosis research to human therapies requires addressing specific challenges.
- Improved experimental models and strategies are needed for antifibrotic drug development.
- Overcoming translational hurdles is crucial for treating chronic liver diseases.
